Imsoft CA’sImmusoft Corporation, a wholly owned subsidiary of Immusoft Corporation, headquartered in San Francisco, California, is a clinical-stage cell therapy company dedicated to improving the lives of patients with rare or genetic diseases and a California regenerative medicine research company. Raised $8 million in funding from CIRM.
The company plans to use the funds to advance its engineered B-cell clinical program. This funding will support a Phase I trial evaluating the safety and tolerability of ISP-001 (for delivery of alpha-L-iduronidase or IDUA) in MPS I, a rare childhood genetic disease.
Immusoft is driving ISP-001, led by Chief Executive Officer Sean Ainsworth and Chief Scientific Officer Robert Hayes. This is a novel platform that uses cell therapy to deliver gene-encoded pharmaceuticals. This platform harnesses the natural ability of her B cells to produce high levels of antibody protein. This is her B-cell therapy that has been genetically engineered to enter human clinical trials. With ISP-001, a patient’s B cells are programmed to constantly produce therapeutic proteins, potentially reducing the need for frequent infusions and improving patient outcomes. There is a nature.
The company has received FDA orphan drug designation and rare pediatric disease designation for ISP-001 for MPS I (mucopolysaccharidosis type I).
In addition to supporting the MPS I clinical trial, in November 2021, Immusoft received a $4 million CIRM grant to support the development of MPS II’s ISP-002 (for the delivery of iduronate sulfatase) program. rice field. Immusoft also entered into a research collaboration and licensing option agreement with Takeda Pharmaceutical Company Limited to provide protein therapeutics that cross the blood-brain barrier to treat neurometabolic disorders.
Fin SME
2023/01/28
